For many research sites, navigating the clinical trial landscape can be very intimidating. Site networks offer many benefits to research sites, but here are five main reasons why every clinical research site should consider joining a site network:
Site selection is a complex process composed of multiple factors on which research sites are evaluated. It may seem as if your success is solely in the hands of sponsors and CROs, but there are several things you can do to help your site get selected on more studies. Here are three tips from the site selection and business development team at PharmaSeek:
Advertising plays an important role when it comes to recruiting patients for clinical trials, but it’s often underutilized by sites or not used at all. Whether this is due to a lack of internal staffing or expertise, there is a lot of potential going untapped when sites bypass study advertising.
A Clinical Trial Management System (CTMS) is a computer software system that manages data within a clinical trial. The system centralizes the administrative components of each study, including billing, reporting and tracking. Many research sites, institutions, sponsors, and CROs use these systems to monitor clinical trials. Below are 3 key benefits of implementing a CTMS.
Finding research sites that are capable and willing to conduct your clinical trials can be a burdensome task. Since 1995, Pharmaseek has partnered with both sponsors and CROs to identify clinical research sites for clinical trials in virtually every therapeutic area. What started as a group of twelve research sites has grown into a network of approximately 250 investigative research sites, the largest network of its kind. Research facilities in the PharmaSeek network range from small practices to large academic institutions.
Much has been written about the changing clinical research landscape, and more importantly, the implications these changes are having on small, independent research sites. The first major change was the implementation of preferred site programs by many larger contract research organizations (CROs). The second, and more recent development, is the actual acquisition of research sites and site networks by CROs. Separate of both of these trends, is the premise that “big data” will give larger health systems a competitive advantage, allowing them to reestablish their dominance in Phase II and III research. Each of these themes are explored in greater detail below.